Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Practical guidelines for evaluating lead exposure in children with mental health conditions: molecular effects and clinical implications.

Burke MG, Miller MD.

Postgrad Med. 2011 Jan;123(1):160-8. doi: 10.3810/pgm.2011.01.2256.

PMID:
21293095
2.

Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders.

Frye RE, Rossignol DA.

Pediatr Res. 2011 May;69(5 Pt 2):41R-7R. doi: 10.1203/PDR.0b013e318212f16b. Review.

3.

Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

Rossignol DA, Frye RE.

Mol Psychiatry. 2012 Mar;17(3):290-314. doi: 10.1038/mp.2010.136. Epub 2011 Jan 25. Review.

4.

Mitochondrial DNA deletion mutations in patients with neuropsychiatric symptoms.

Kato M, Nakamura M, Ichiba M, Tomiyasu A, Shimo H, Higuchi I, Ueno S, Sano A.

Neurosci Res. 2011 Apr;69(4):331-6. doi: 10.1016/j.neures.2010.12.013. Epub 2010 Dec 24.

PMID:
21185889
5.

Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains.

Kleinman JE, Law AJ, Lipska BK, Hyde TM, Ellis JK, Harrison PJ, Weinberger DR.

Biol Psychiatry. 2011 Jan 15;69(2):140-5. doi: 10.1016/j.biopsych.2010.10.032. Review.

6.

Mitochondrial DNA (mtDNA) and schizophrenia.

Verge B, Alonso Y, Valero J, Miralles C, Vilella E, Martorell L.

Eur Psychiatry. 2011 Jan;26(1):45-56. doi: 10.1016/j.eurpsy.2010.08.008. Epub 2010 Oct 25. Review.

PMID:
20980130
7.

Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia.

Clay HB, Sillivan S, Konradi C.

Int J Dev Neurosci. 2011 May;29(3):311-24. doi: 10.1016/j.ijdevneu.2010.08.007. Epub 2010 Sep 15. Review.

8.

The role of mitochondrial dysfunction in psychiatric disease.

Scaglia F.

Dev Disabil Res Rev. 2010;16(2):136-43. doi: 10.1002/ddrr.115. Review.

PMID:
20818728
9.

Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.

Bertoglio K, Jill James S, Deprey L, Brule N, Hendren RL.

J Altern Complement Med. 2010 May;16(5):555-60. doi: 10.1089/acm.2009.0177.

PMID:
20804367
10.

Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.

Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J.

Brain Behav Immun. 2011 Jan;25(1):40-5. doi: 10.1016/j.bbi.2010.08.003. Epub 2010 Aug 10.

11.

Improving the prediction of response to therapy in autism.

Bent S, Hendren RL.

Neurotherapeutics. 2010 Jul;7(3):232-40. doi: 10.1016/j.nurt.2010.05.011. Review.

12.

Toxicity biomarkers in autism spectrum disorder: a blinded study of urinary porphyrins.

Kern JK, Geier DA, Adams JB, Mehta JA, Grannemann BD, Geier MR.

Pediatr Int. 2011 Apr;53(2):147-53. doi: 10.1111/j.1442-200X.2010.03196.x.

PMID:
20626635
13.

Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides.

Bouchard MF, Bellinger DC, Wright RO, Weisskopf MG.

Pediatrics. 2010 Jun;125(6):e1270-7. doi: 10.1542/peds.2009-3058. Epub 2010 May 17.

14.
15.

Mercury induces inflammatory mediator release from human mast cells.

Kempuraj D, Asadi S, Zhang B, Manola A, Hogan J, Peterson E, Theoharides TC.

J Neuroinflammation. 2010 Mar 11;7:20. doi: 10.1186/1742-2094-7-20.

16.

Neuroinflammation in Alzheimer's disease and major depression.

Dobos N, Korf J, Luiten PG, Eisel UL.

Biol Psychiatry. 2010 Mar 15;67(6):503-4. doi: 10.1016/j.biopsych.2010.01.023. No abstract available.

PMID:
20185031
17.

Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report.

Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H.

Pediatrics. 2010 Jan;125 Suppl 1:S1-18. doi: 10.1542/peds.2009-1878C.

PMID:
20048083
18.

Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006.

Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2009 Dec 18;58(10):1-20. Erratum in: MMWR Surveill Summ. 2010 Aug 6;59(30):956.

19.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J.

BMC Clin Pharmacol. 2009 Oct 23;9:17. doi: 10.1186/1472-6904-9-17.

20.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J.

BMC Clin Pharmacol. 2009 Oct 23;9:16. doi: 10.1186/1472-6904-9-16.

Supplemental Content

Support Center